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Abstract
Mitochondrial stress elicits the production of stress response molecules indicated as mitokines, including fibroblast growth factor 21 (FGF21), 
growth differentiation factor 15 (GDF15), and humanin (HN). Many diseases are characterized by progressive mitochondrial dysfunction 
with alterations of mitokine secretion. It is still controversial whether healthy aging and extreme longevity are accompanied by an altered 
production of mitokines. We analyzed FGF21, HN, and GDF15 plasma levels in 693 subjects aged from 21 to 113 years, and the association 
of these mitokines with parameters of health status. FGF21, HN, and GDF15 resulted increased in old age, with the highest levels found in 
centenarians. These molecules are associated with worsened parameters (such as handgrip strength, insulin sensitivity, triglycerides), particularly 
in 70-year-old persons, and their levels are inversely correlated with survival in the oldest subjects. Considering the positive biological effect 
of these molecules, our results can be interpreted in the framework of the hormetic paradigm as an attempt of the cells/tissues to cope with 
a stress that can have beneficial or detrimental effects depending on its intensity. Finally, persons with Down Syndrome (characterized by 
accelerated aging) have higher levels of GDF15 and HN with respect to their siblings, suggesting that these molecules, especially GDF15, could 
be considered markers of biological age.
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Over the past years, a great number of studies have been devoted 
to clarify the cellular and molecular mechanisms of human aging. 
Among these mechanisms, mitochondrial dysfunction and reac-
tive oxygen species (ROS) production have been long considered as 
one of the principal causes of aging (1,2). However, more recently, 
this theory has been questioned by data showing that the complete 
elimination of oxidative stress actually does not extend life span in 
animal models (3,4), while a mild mitochondrial dysfunction may 
contribute to an increase of life span (5,6). This beneficial effect of 
mitochondrial dysfunction is mediated by increased mitophagy and 
a series of stress response mechanisms including the mitochondrial 
variant of unfolded protein response (UPRmt). These responses can 
elicit protective effects not only in the affected cell but also in distant 
cells/tissues. As an example, in Caenorhabditis elegans, the induction 
of UPRmt in the nervous system activates the same response in the 
intestine, leading eventually to a positive effect on life span (7). 
Likewise, in Drosophila melanogaster, the moderate knock-down of 
some electron transport chain components in specific tissues, such as 
brain or muscle, is sufficient to promote organismal longevity (8,9). 
Interestingly, a threshold effect has been noticed, where moderate 
dysfunction resulted in life extension, while strong dysfunction was 
detrimental (5,8). The mitochondrial defects that can activate the ret-
rograde response range from autophagy defects (eg, Atg7 disruption), 
deletion of mitofusin 1 and 2 leading to disorganised mitochondria 
(10), to inhibition of respiratory complex I (11). This distal response 
can delay the aging process and elicit life span extension in animal 
models, including rodents, likely by improving systemic viability 
through the coordination of cellular stress responses (8,12–14). Dillin 
and coworkers hypothesized that the spreading of this response to 
distal tissues occurs via soluble factors indicated as “mitokines” (7). 
In fact, a number of mitokines produced and secreted in response to 
a mitochondrial stress have been identified. Some of these mitokines 
are nuclear encoded and are expressed in response to UPRmt. These 
include, among others, fibroblast growth factor 21 [FGF21; (10)] and 
growth differentiation factor 15 [GDF15; (15)].
FGF21 is a hormone-like member of FGF family involved in meta-
bolic processes, also described as stress hormone for its role as a potent 
longevity factor (16). Several findings demonstrate that the overexpres-
sion of FGF21 improves healthspan and that FGF21 is normally secreted 
from several tissues in response to an acute local stress. Higher levels of 
circulating FGF21 attenuate acute metabolic disorders and collaborate 
to extend life span (16,17). Despite its multiple beneficial effects, other 
studies indicate that circulating levels of FGF21 are elevated in several 
metabolic diseases, such as type 2 diabetes (18). Moreover, when chron-
ically expressed, FGF21 increases with age in humans and contributes 
to precocious aging and premature death in mice (19,20). In this con-
text, whether FGF21 is beneficial or detrimental is still debated.
GDF15 is a member of the transforming growth factor (TGF)-β 
family, produced by several tissues. It is considered as an indicator 
of mitochondrial dysfunction in muscle (21), and it has cardiopro-
tective and neuroprotective activity. GDF15 regulates appetite and 
energy metabolism under both physiological and pathological condi-
tions, possibly through a modulation of mitochondrial functions, as 
it can affect mitochondrial biogenesis, thermogenesis, and fatty acid 
metabolism (22). Interestingly, mice overexpressing human GDF15 
display increased life span (23). However, it is also known that cir-
culating levels of GDF15 are associated with cardiovascular diseases, 
insulin resistance and type 2 diabetes, neurodegeneration, and over-
all mortality (24,25). It has been therefore speculated that GDF15 
can be secreted as a consequence of various cellular stresses and 
dysfunctions and might compensate for mitochondrial dysfunction 
during aging and age-related diseases, as well as in mitochondrial 
diseases (22). Like FGF21, also for GDF15, the biological signifi-
cance of this molecule is not totally clear. Several observations, in 
fact, indicate that GDF15 could have a positive or a negative role 
depending on the state of the cell and its environment (24).
In addition to nuclear-encoded mitokines, it is known that a 
number of peptides encoded by mitochondrial DNA, including 
humanin [HN; (26,27)], mitochondrial open reading frame of the 
12S rRNA-c [MOTS-c; (28)] and six additional peptides encoded 
in the same mitochondrial DNA region, indicated as small huma-
nin-like peptides [SHLPs; (29)], are likely produced in response to 
mitochondrial stress (30) and have anti-apoptotic and neuroprotec-
tive effects. HN is the first mitochondrial-derived peptide secreted 
in plasma described for its cytoprotective role in several age-related 
diseases, such as Alzheimer’s disease, diabetes, hepatic steatosis, ath-
erosclerosis, and cardiovascular diseases. However, the role of HN in 
aging and age-related diseases is not completely understood.
A progressive mitochondrial dysfunction is known to occur with 
age (31–33). In particular, we have reported that dermal fibroblasts 
from centenarians but not from 70-year-old subjects display a com-
pensated mitochondrial dysfunction, characterized by decreased 
complex I-driven ATP synthesis and increased H202 production (34). 
It is presently unknown whether such a decreased functionality is suf-
ficient to trigger a rise in the level of mitokines, and, more in general, 
the correlation between mitokine production, aging, and longevity in 
humans has not been deeply explored. We reasoned that centenarians, 
that is, the best example of extreme longevity and successful aging, 
could be characterized by a peculiar expression of mitokines. To test 
this hypothesis, we measured the circulating levels of the previously 
described mitokines, FGF21, GDF15, and HN in the plasma of about 
693 volunteers of different age, from 21 to 113 years. Moreover, we 
evaluated the association between mitokines and a series of param-
eters related to health status and phenotype, and we analyzed the sur-
vival of >90-year-old persons according to their levels of mitokines.
Materials and Methods
Subjects
A total of 693 subjects in the age range from 21 to 113 years were 
recruited and divided into four age groups: 79 young/adult subjects 
(YA, age range 21–59 years), 336 elderly (EL, age range 61–79 years), 
155 oldest old (OO, age range 82–99  years) and 123 centenarians 
(CENT, age range 100–113 years; Supplementary Table 1). All subjects 
were enrolled in Italy in the framework of the following projects: Italian 
National Project PRIN06 and PRIN09 for EL and centenarian subjects, 
EU Project GEHA for oldest old subjects, EU Project NUAGE for EL.
A total of 28 sibling pairs constituted by a person with Down syn-
drome (age range 11–43 years) and a nontrisomic sibling (age range 
8–52 years) were collected in the framework of an Italian project on 
intellectual disability supported by CARISBO Foundation. The study 
protocols were approved by the Ethical Committee of Sant’Orsola-
Malpighi University Hospital (Bologna, Italy). All subjects signed the 
informed consent before blood withdrawal, functional and anthropo-
metric measurement, and interviews (health status, clinical anamnesis). 
A standard questionnaire was administered by trained physicians and 
nursing staff to collect demographic and lifestyle data, anthropometric 
measurements, functional, cognitive and health status, clinical anam-
nesis, and details on drug use. As for OO and CENT, in all cases where 
the subject was unable to respond autonomously because of hearing 
or sight problems, the interview was performed with a relative or a 
caregiver. Subjects affected by malignant neoplasia and/or those in 
therapy with immune suppressor drugs (like cyclosporine, methotrex-
ate, glucocorticoids, etc.) or anticoagulant drugs were excluded from 
the study. As far as health status, YA, EL, and OO subjects were free 
of clinically evident major diseases. CENT were more heterogeneous. 
Supplementary Table 2 shows the prevalence of the major age-related 
diseases in CENT group. However, it is to note that the age at onset of 
such diseases is very advanced, further supporting the idea that cente-
narians are model of successful aging.
Data Collection
Body mass index (BMI) was calculated as weight in kilograms divided 
by the square of the height in meters (kg/m2). Handgrip strength 
test was performed to measure the maximum isometric strength 
of the hand and forearm muscles using a hand-held dynamometer 
(SMEDLYS’ dynamometer, Scandidact, Kvistgaard, Denmark) for 
two performances with each hand.
Blood was drawn in the morning after an overnight fast. All 
samples were processed immediately to collect serum and plasma. 
Serum was obtained after clotting and centrifugation at 760g for 
20 minutes at 4°C, rapidly frozen and stored at −80°C. Plasma was 
obtained within 2 hours from venipuncture by centrifugation at 
2,000g for 20 minutes at 4°C, rapidly frozen and stored at −80°C.
Total and HDL cholesterol, triglycerides, C-reactive protein 
(CRP), glycaemia, insulin, albumin, total protein, uric acid, and cre-
atinine were measured in serum by standard biochemical assays. 
Insulin resistance status was assessed using the homeostasis model 
assessment of insulin resistance (HOMA-IR), according to the pre-
viously described formula (35): insulin (in microunits per milliliter) 
× glucose (in millimoles per liter)/22.5. The median value of func-
tional, metabolic, biochemical, and inflammatory parameters for 
each group was reported in Supplementary Table 1.
FGF21, GDF15, and HN concentrations were determined in 
plasma samples by ELISA assay using commercial kits, R&D for 
FGF21 (DF2100; intra- and interassay CV range: 10.2%–3.0% 
and 10.6%–3.1%, respectively) and GDF15 (DGD150; intra- and 
interassay CV range: 10.9%–1.1% and 4.1%–3.0%, respectively); 
CUSABIO for HN (CSB-EL015084HU; intra- and interassay CV 
range: 5.5%–0.7% and 11.8%–3.4%, respectively), according to 
the manufacturer’s instructions. For all the samples, FGF21, GDF15, 
and HN were analyzed in a blind setup.
Data on IGF-1 plasma level were available for 137 subjects (62 
EL, 24 OO, and 51 CENT) from a previous study (36).
Total IGF-1 was assayed by one-step sandwich chemilumines-
cence immunoassay (CLIA) after prior separation of IGF-1 from 
binding proteins on the Liaison autoanalyzer (DiaSorin, Saluggia, 
Italy). Samples were acidified to separate IGF-1 from binding pro-
teins, and excess IGF-2 was used after acidification to avoid residual 
interference IGF-1 with binding proteins. Intra-assay and interassay 
CVs were 4.4% and 5.5%, respectively. The mean recovery value 
was 97% of the hypothetical expected amount.
Statistical Analysis
The correlation between mitokines and age and among mitokines were 
calculated by Spearman rank correlation. The association between 
mitokines and parameters related to health status and phenotype 
(BMI, handgrip strength, glucose metabolism, lipid profile, and other 
biochemical markers) was evaluated by a multivariate general lin-
ear model adjusted for age, gender, and therapies in each age group. 
Gender differences were assessed by Mann–Whitney U test. EL, 
OO, and CENT subjects were clustered according to their mitokines 
(FGF21, HN, GDF15) levels by a two-step cluster analysis. Cumulative 
survival curves were employed to display 5-year all cause mortality 
according to clusters in nonagenarians and centenarians. The associ-
ation between clusters and mortality was evaluated by a Cox regres-
sion model adjusted for age and gender in OO and CENT. All analyses 
were executed using SPSS 23.0 for Windows (SPSS, Inc., Chicago, IL).
Results
Plasma Levels of Mitokines Increase With Age and 
Are Correlated With Each Other
The plasmatic levels of FGF21, HN, and GDF15 are positively and 
significantly correlated with age (Figure  1A–D). Moreover, these 
are correlated with each other (Figure 1E–H). Slight but significant 
differences between men and women were present in some age 
groups (Supplementary Figure 1). In particular, FGF21 is higher in 
YA men (p  =  .016) and in OO women (p  =  .016; Supplementary 
Figure  1A), while GDF15 is higher in EL men (p  =  .001; 
Supplementary Figure 1B). No gender differences were observed for 
HN (Supplementary Figure 1C).
It is reported that the levels of HN decrease with age (37). Our 
results were thus in contrast with literature data. We tried to confirm 
our results on HN by analyzing the association with IGF-1, which 
is reported to suppress HN level in plasma (38). The data regarding 
IGF-1 plasma levels were available for 137 subjects (62 EL, 24 OO, 
and 51 CENT). We found a negative correlation between HN and 
IGF-1 (Spearman rank correlation: ρ = −0.259; p = .002) and these 
data indicate that the high levels of HN found in old age are paral-
leled, as expected, by low levels of IGF-1.
Figure 1. Correlation analysis of mitokines in young/adult (YA), elderly (EL), 
oldest old (OO), and centenarians (CENT). (A–C) Scatter plot of age vs fibroblast 
growth factor 21 (FGF21) (A), humanin (HN) (B), growth differentiation factor 
15 (GDF15) (C); (D) Spearman rank correlation coefficients (ρ, rho) between 
age and FGF21, HN, and GDF15. (E–G) Scatter plot of FGF21 vs HN (E), FGF21 
vs GDF15 (F), HN vs GDF15 (G); (H) Spearman rank correlation coefficients 
(ρ) among mitokines.
FGF21, HN, and GDF15 Plasma Levels Are 
Associated With Worsening of Functional and 
Biochemical Parameters, Particularly in EL Subjects
An association analysis between plasma levels of mitokines and 
functional, metabolic, biochemical, and inflammatory parameters 
(BMI, handgrip strength, HOMA-IR index, HDL cholesterol, tri-
glycerides, CRP, albumin, total protein, uric acid, and creatinine) was 
performed in each age group according to a general linear model 
adjusted for age, gender, and therapies (Supplementary Table  3, 
panel A and B). The association between cognitive status (assessed 
by Mini-Mental State Evaluation) and mitokines was also evaluated, 
and no significant association was found (data not shown). Plasma 
FGF21 level is positively associated with BMI in EL and with tri-
glycerides in both EL and OO (Supplementary Table 3, panel A); it 
is positively associated also with uric acid in EL and with CRP in 
OO, and negatively associated with total protein content in CENT 
(Supplementary Table  3, panel B). HN plasma level is associated 
negatively with BMI in EL and positively with triglycerides in CENT 
(Supplementary Table  3, panel A); it is associated negatively with 
albumin in EL and positively with creatinine in OO (Supplementary 
Table 3, panel B). Plasma GDF15 level is positively associated with 
BMI, HOMA-IR and triglycerides in EL, and negatively associated 
with handgrip strength in both EL and OO (Supplementary Table 3, 
panel A); it is positively associated with CRP in CENT and with 
creatinine in both OO and CENT (Supplementary Table 3, panel B). 
GDF15 and uric acid were positively associated in YA and negatively 
in EL, OO, and CENT (Supplementary Table 3, panel B).
These data show that increased levels of mitokines (in particular, 
GDF15) are associated with worsening of functional and biochem-
ical parameters (reduction of handgrip strength, HDL cholesterol, 
serum albumin and total proteins, and increase of BMI, HOMA-IR 
index, triglycerides, and uric acid), particularly in EL subjects. In 
fact, among the 20 significant associations, half of them are found in 
EL group. For this reason, a two-step cluster analysis was performed 
in this group according to the plasma levels of mitokines. Two clus-
ters of EL subjects were identified: one with high levels of mitokines 
(HL), and another with low levels of mitokines (LL; Table 1). No 
difference in gender distribution was observed between clusters. LL 
group has lower BMI, lower glucose metabolism and insulin resist-
ance markers (glycaemia, insulin, HOMA-IR), a better lipid profile 
(higher HDL cholesterol, lower triglycerides), lower CRP and cre-
atinine compared with HL group (Table 1).
Nonagenarian Subjects and Centenarians With 
Lower Levels of Mitokines Have a Slight Survival 
Advantage
As a whole, the data previously described suggest that circulating 
levels of mitokines are strongly associated with age and with param-
eters indicative of the health status. Taking advantage of the het-
erogeneity of the CENT group regarding morbidity, we could split 
this group into three subgroups (0–2 diseases; 3–4 diseases; and ≥5 
diseases). No significant difference in mitokines levels was found 
among the three subgroups (data not shown). We then wondered 
whether these mitokines are also associated with survival. Taking 
advantage of the mortality follow-up available for the subjects over 
90  years of age, we performed a survival analysis on nonagenar-
ians (90–99  years) and CENT (100–113  years). Both nonagenar-
ians and CENT were clustered according to the plasma levels of 
FGF21, HN, and GDF15 by a two-step cluster analysis. As previ-
ously described, this cluster analysis divided the subjects into two 
groups, one with high levels of mitokines (HL), and another with 
low levels of mitokines (LL).
Concerning nonagenarians, the LL group shows higher handgrip 
strength (p = .007) and lower levels of albumin (p = .018), uric acid 
(p = .000), and creatinine (p = .001) with respect to the HL group 
(Figure 2A). No significant differences for other metabolic and bio-
chemical parameters were observed (data not shown). Moreover, LL 
group has a significantly longer estimated survival time compared 
with the HL group (p  =  0.000). Figure  2B shows the cumulative 
survival curves for the two groups and the association with the mor-
tality estimated by univariate Cox regression model adjusted for age 
and gender. The HL group shows an increased hazard and increased 
mortality rate compared the LL group used as reference (p = .000; 
Figure 2B).
In CENT, the LL group shows lower level of creatinine (p = .002) 
and higher insulin (p = .007) and HOMA-IR (p = .006) in compari-
son with the HL group (Figure 3A). No significant differences for 
other parameters (functional, biochemical, metabolic, and inflam-
matory markers) were observed (data not shown). Similar to what 
we observed in nonagenarians, also in CENT the LL group has a 
Table 1. Functional and Biochemical Parameters in EL Subjects Clustered According to Plasma Levels of Mitokines
Group (N) LL (273) HL (63) p
Men/women (N) 127/146 36/27 .130
Age, mean (SD) 71.0 (4.0) 72.7 (3.9) .011
FGF21 (pg/mL) 284.1 [201.2] 431.5 [445.8] .000
HN (pg/mL) 1086.2 [636.8] 1047.1 [800.9] .876
GDF15 (pg/mL) 952.0 [358.4] 1835.2 [531.5] .000
BMI (kg/m2) 26.6 [4.6] 28.6 [5.0] .007
Glycemia (mg/dL) 98.2 [14.7] 103.2 [21.0] .012
Insulin (µU/mL) 8.6 [7.9] 10.0 [8.5] .007
HOMA-IR index 2.0 [2.0] 2.6 [2.6] .002
Total cholesterol (mg/dL) 200.0 [44.6] 186.5 [49.5] .036
HDL cholesterol (mg/dL) 55.9 [22.0] 49.8 [25.7] .015
Triglycerides (mg/dL) 96.3 [49.7] 107.6 [78.7] .037
C-reactive protein (mg/L) 1.0[1.7] 1.3 [2.5] .012
Creatinine (mg/dL) 0.8 [0.2] 0.9 [0.3] .003
Notes: LL = subjects with low levels of mitokines; HL = subjects with high levels of mitokines. Statistical analysis was performed by Mann–Whiney U test. Age 
is reported as mean (SD = standard deviation), other data are shown as median [IQR = interquartile range].
significantly longer estimated survival time compared with HL 
group (p = .039; Supplementary Table 5). Finally, HL group shows 
an increased hazard and increased mortality rate compared to LL 
group used as reference (p = .018; Figure 3B).
To understand which mitokine, among FGF21, HN, and GDF15, 
has the greater influence on mortality, a further association analysis 
was performed. Supplementary Table  4 shows the association of 
every  single mitokine with mortality in nonagenarians and CENT 
estimated by a Cox regression model with log-transformed variables 
adjusted for age and gender. According to this analysis, GDF15 is the 
most associated mitokine (p = .006; Supplementary Table 4).
It is well known that handgrip strength is a strong predictor 
of mortality. To further investigate whether these mitokines syner-
gize with handgrip strength in predicting mortality, we performed 
a multivariate Cox regression with forward stepwise selection. 
We confirmed that handgrip strength is associated with mortal-
ity (Supplementary Table 5, Model 1). Among the mitokines, only 
GDF15 was able to improve the prediction capability of handgrip 
strength (Supplementary Table 5, Model 2).
GDF15 and HN Are Higher in Subjects With Down 
Syndrome With Respect to Their Nontrisomic 
Siblings
As a whole, these data suggest that mitokines could be considered 
a sort of marker for biological age. To find support to this idea, we 
investigated the plasma levels of mitokines in subjects with Down 
syndrome (DS), a condition characterized by segmental accelerated 
aging. We measured mitokines plasma levels in 28 adults with DS 
and their nontrisomic siblings. Although no difference is observed in 
mean age (p = .436), DS subjects have higher plasma levels of HN 
(p  =  .014) and GDF15 (p  =  .001) in comparison to their siblings 
(Supplementary Table 6).
Figure  2. Functional parameters and survival analysis in nonagenarians 
clustered according to the plasma levels of mitokines. (A) Mitokines, body 
mass index (BMI), handgrip strength, albumin, uric acid and creatinine 
levels, and estimated survival time in nonagenarians clustered according 
to their fibroblast growth factor 21 (FGF21), humanin (HN), and growth 
differentiation factor 15 (GDF15) plasma levels (LL =  low levels; HL = high 
levels). Age is reported as mean (SD  =  standard deviation), other data 
are shown as median [IQR  =  interquartile range]. Statistical analysis was 
performed by logistic regression for gender, Mann–Whiney U test for age, 
mitokines, BMI, handgrip strength, albumin, uric acid and creatinine levels, 
and logrank (Mantel–Cox) for estimated survival time. (B) Cumulative 
survival curves in nonagenarians clustered according to their FGF21, HN, 
GDF15 plasma levels, and mortality estimated by Cox regression model 
adjusted for age and gender. Nonagenarians belonging to LL cluster were 
considered the reference for the regression analysis.
Figure 3. Functional parameters and survival analysis in centenarians (CENT) 
clustered according to the plasma levels of mitokines. (A) Mitokines, insulin 
resistance markers, creatinine levels, and estimated survival time in CENT 
clustered according to their fibroblast growth factor 21 (FGF21), humanin 
(HN), growth differentiation factor 15 (GDF15) plasma levels (LL = low levels; 
HL = high levels). Age is reported as mean (SD = standard deviation), other 
data are shown as median [IQR = interquartile range]. Statistical analysis was 
performed by logistic regression for gender, Mann–Whiney U test for age, 
mitokines, insulin resistance markers, creatinine levels, and logrank (Mantel–
Cox) for estimated survival time. (B) Cumulative survival curves in CENT 
clustered according to their FGF21, HN, GDF15 plasma levels, and mortality 
estimated by Cox regression model adjusted for age and gender. CENT 
belonging to LL cluster were considered the reference for the regression 
analysis.
Discussion
Dillin and coworkers hypothesized some years ago that a mito-
chondrial stress could elicit beneficial effects on health and life span 
spreading at organismal level through soluble elements putatively 
indicated as mitokines (7), and many data indicate indeed that a 
mild mitochondrial dysfunction actually promotes longevity (5,6). 
Since then, a number of molecules that are synthesized in response 
to mitochondrial stress have been identified, including FGF21 (10) 
and GDF15 (15). The previously discovered 24-aa peptide encoded 
by mitochondrial DNA indicated as HN also fulfilled the features of 
a mitochondrial retrograde response molecule (39). We have recently 
proposed the existence of a sort of “mitochondrial hormesis” (40). 
According to this idea, the presence of a mild mitochondrial dysfunc-
tion that can elicit the production of effective stress responses and 
metabolic adaptations (including mitokines production) would be 
more beneficial for health and longevity than a network of perfectly 
functioning mitochondria (38). In agreement with this hypothesis, 
we have demonstrated that dermal fibroblasts from centenarians 
have partially impaired mitochondria (34). However, mitochondrial 
dysfunction has been recently shown to be sufficient to accelerate 
aging process and cause premature death (20).
With this in mind, in this study, we analyzed the levels of 
FGF21, HN, and GDF15 in a cohort of subjects whose age spans 
from 21 to 113 years. We also evaluated the potential association 
of these mitokines with functional, metabolic, and biochemical 
parameters as well as survival (where available). Here, we report 
that the circulating levels of these mitokines increase with age. 
However, it is to note that the correlation with age of GDF15 is 
much higher than that of FGF21 and HN. Although the nature 
of the interaction among these mitokines is not yet totally clear, 
these data actually indicate that GDF15 is more affected by aging 
and it could be considered a potential marker of age. The levels of 
these mitokines become maximal in centenarians, indicating that 
the biological mechanisms that trigger their increase are still active 
in extreme old age.
These data are in agreement with previous literature as far as 
FGF21 and GDF15, which are reported to increase with age in both 
animal models and humans (19,20,22). On the contrary, a study by 
Muzumdar and coworkers (37) reported a decrease of HN levels 
with age in humans (37). It is to note that as we used a commer-
cial kit for HN, while Muzumdar and coworkers as well as other 
groups used an antibody developed in-house. However, the commer-
cial antibody that we used is raised against the mitochondrial pep-
tide of HN (http://www.uniprot.org/uniprot/Q8IVG9#sequences) 
and no significant cross-reactivity or interference with the analogues 
of HN tested so far has been observed. Moreover, in the article by 
Muzumdar and coworkers reporting such a decrease, no descrip-
tion of the human samples analyzed is provided, so a comparison 
with our data is not possible (37). Our data are further supported 
by the negative correlation found between the plasma levels of HN 
and IGF-1. It is reported in fact that IGF-1 levels and bioavailability 
decrease with age (36,41), and that IGF-1 inhibits the production 
of HN (38).
The fact that the circulating levels of the three mitokines con-
sidered in this study increase with age fit with the idea that aging is 
characterized by progressive mitochondrial stress. As stress response 
molecules, these mitokines are reported to have many beneficial 
effects for the cells and the whole organism. In particular, FGF21 
has cardioprotective effects (42), positive metabolic effects, includ-
ing weight loss, improved glycemia, and decreased inflammation 
(43), it delays immunosenescence (44), and increases the life span of 
animals in experimental models (16); HN is a neuroprotective factor 
that negatively regulates apoptosis, insulin resistance, and inflam-
mation (27,29) and it plays a protective role in many pathologies 
such as Alzheimer’s disease, cardiovascular diseases, type 2 diabetes, 
inflammation, as reviewed by Gong and coworkers (45); GDF15 
has reported cardioprotective and neuroprotective activity, and it 
can affect mitochondrial biogenesis and fatty acid metabolism (22). 
Moreover, mice overexpressing human GDF15 display increased life 
span (23). Therefore, given these premises, we would have expected 
that, within each age group, the subjects characterized by higher lev-
els of mitokines would be healthier. To our surprise, this was not 
the case. In fact, we found that the levels of these mitokines are 
associated with worsened functional and biochemical parameters 
(higher BMI and insulin resistance, low handgrip strength, higher 
CRP, triglycerides, uric acid, and creatinine) in EL and decreased 
survival in the oldest groups (nonagenarians and CENT). GDF15 
resulted the most powerful predictor of mortality among the three 
mitokines, being also able to improve the predictive power of mor-
tality reported for handgrip strength. At variance, FGF21 and HN 
were less strongly associated with mortality.
It is, however, to note that a great debate exists on the precise 
role of these mitokines in aging and diseases. In particular, the role 
of FGF21 has been questioned, as it appears possibly dispensable 
for the metabolic improvements evoked by compromised mitochon-
drial function in skeletal muscle (46). Moreover, FGF21 appears also 
to be responsible for the accelerated aging phenotype when mito-
chondrial dysfunction is induced by acute inhibition of the fusion 
protein OPA1 (20). These data suggest that chronically high blood 
levels of FGF21 contribute to unhealthy aging. On the same vein, 
circulating levels of GDF15 have been found associated with car-
diovascular diseases, insulin resistance and type 2 diabetes, neurode-
generation and overall mortality [reviewed in Fujita and coworkers 
(22)]. However, it is unlikely that these mitokines are detrimental 
per se. Rather, they may represent the attempt of the cell/tissue to 
cope with an ongoing stress. According to the concept of hormesis, 
whether this coping will be successful strictly depends on the inten-
sity of the stress (47). If the stress is mild and possibly transient, 
the mitokines can efficiently cope with it and strengthen the organ-
ism; on the contrary, a stronger and possibly chronic stress can have 
detrimental effects, either because these effects are too intense and 
mitokines are not able anymore to counteract them, or mitokines 
may cause themselves a metabolic stress condition when secreted at 
excessive concentration. Whatever could be the reason, the net result 
is that a correlation emerges between mitokines levels and wors-
ened health status. This hypothesis is depicted in Figure  4, where 
we speculated that mitokines production turns from protective to 
detrimental adaptive response, as the level of mitokines increases as 
it occurs during aging.
As a whole, it seems that these mitokines are associated with 
biological age. The quest for markers of biological age is a hot topic 
of modern Geroscience. In recent years, we and others have identi-
fied some powerful markers of biological age, such as methylation 
of specific CpG islands of ELOVL2 and FHL2 genes, and circulating 
N-glycan profiles. Accordingly, these biomarkers resulted significantly 
elevated in DS persons, indicating that, actually, these subjects experi-
ence an accelerated aging (48,49). To verify if these mitokines could 
be provisionally added to the list of putative markers of biological 
age, we studied their levels in a group of DS persons. We have found a 
higher level of HN and GDF 15 in DS subjects, in comparison to their 
sibling. In addition, GDF15 has been shown to be a predictor of physi-
cal decline in old subjects (50), therefore, it seems that (at least some 
of) these mitokines could be added to the list of the markers of bio-
logical age. Further studies are needed to fully confirm this hypothesis.
Conclusions
As a whole, our results show for the first time that plasma levels of 
three representative mitokines, FGF21, GDF15, and HN, are posi-
tively correlated with age in humans, and become maximal in cente-
narians. This correlation is particularly marked for GDF15.
The physiological in vivo effects of mitokines are apparently 
not straightforward. Studies in the literature report both positive 
and negative effects of these molecules. Our data indicate that the 
circulating levels of FGF21, GDF15, and HN are associated with 
worsened health parameters and with mortality in old age, and the 
predominant association is observed for GDF15. Although it can 
only be speculated that the role of mitokines turns detrimental as 
they increase in concentration, our data are consistent with the idea 
that mitokines (in particular, GDF15) can be considered as markers 
of biological age. This hypothesis is strongly supported by the ana-
lysis of mitokines in DS persons, characterized by segmental accel-
erated aging. These persons show higher levels of HN and GDF15 
with respect to their siblings. Further studies are granted to better 
clarify the biological significance of these findings.
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